Alvotech Set to Showcase 2022 Full Year Financial Results on March 2, 2023

Alvotech, a global biotech leader in the development and manufacture of life-saving biosimilar medicines, will release its financial results for full year 2022 on Wednesday, March 1, 2023 after U.S. markets close. With an unwavering commitment to providing patients with access to high quality, cost-effective treatments, Alvotech is poised to report a year of record-breaking success.

Join us for Alvotech’s business update conference call on Thursday, March 2, 2023 at 8:00 am ET (13:00 pm GMT). Get the inside scoop on their latest news and developments, as well as insights into the future of the company. You won’t want to miss this exclusive investor opportunity – webcast live to members of the news media, investors and the public.

About Alvotech

Alvotech is a global biotech leader in the development and manufacture of biosimilar medicines, dedicated to providing high quality and cost-effective treatments to patients all over the world. Founded by Robert Wessman, Alvotech’s pipeline includes 8 biosimilar candidates to treat autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. With strategic commercial partnerships across the United States, Europe, Japan, China and parts of South America, Africa and the Middle East, Alvotech is able to leverage local expertise and provide global reach. Alvotech is committed to making a difference in the healthcare industry, and is proud to be making a positive impact on the lives of millions of people around the world.

Leave a Comment